Home › Trials › NCT06991257

PF-07328948 for adults with heart failure (BRANCH-HF).

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)

Phase 2 Interventional Pfizer · NCT06991257

This trial will test whether taking PF-07328948 once daily helps adults with heart failure who are already on standard medicines, including SGLT2 inhibitors.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment620 (estimated)
Ages18 Years to 79 Years
SexAll
SponsorPfizer Industry-sponsored
Locations139 sites (Beverly Hills, California and 138 other locations)
Trial IDNCT06991257 on ClinicalTrials.gov

What this trial studies

BRANCH-HF is a phase 2, randomized, placebo-controlled trial testing three dose levels of PF-07328948 versus placebo in adults with heart failure and left ventricular ejection fraction greater than 40%. Participants will take the study medicine or placebo once daily for 36 weeks while continuing standard-of-care treatment including SGLT2 inhibitors. The study follows participants for about 48 weeks with 15 visits total, roughly 10 in-person clinic visits and up to 5 remote contacts. Safety, tolerability, and effects on symptoms and functional capacity will be measured to help define optimal dosing.

Who should consider this trial

Good fit: Adults aged 18–79 with a clinical diagnosis of heart failure for at least 3 months, NYHA class II–IV, left ventricular ejection fraction >40%, and already taking SGLT2 inhibitors are the intended participants.

Not a fit: People with type 1 diabetes, liver cirrhosis, known intolerance or contraindication to SGLT2 inhibitors, those on IV inotropes or listed for transplant, or with conditions that affect drug absorption are unlikely to be eligible or receive benefit from this trial.

Why it matters

Potential benefit: If effective, PF-07328948 could reduce symptoms and improve exercise capacity for people with HFmrEF or HFpEF, providing a new oral treatment option.

How similar studies have performed: Some other heart-failure trials have shown benefit from SGLT2 inhibitors in HFpEF/HFmrEF, but PF-07328948 is a novel investigational medicine currently being tested in early-phase trials.

Eligibility criteria

Show full inclusion / exclusion criteria 
This study is seeking participants who are:

Key Inclusion Criteria include:

* aged 18 years to \< 80 years
* clinically confirmed to have a diagnosis of heart failure for at least 3 months
* New York Heart Association Class II-IV symptoms
* left ventricular ejection fraction greater than 40%
* Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score \< 85
* Six-minute walking distance greater than 75 meters

Key Exclusion Criteria include:

* Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body.
* Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor.
* History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes
* Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor

Where this trial is running

Beverly Hills, California and 138 other locations

+89 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Heart FailureHeart Failure with mildly reduced ejectionHeart Failure with preserved ejection fraction
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.